6. Emergent BioSolutions (EBS - Get Report) is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and antibody therapies for use in preventing and treating disease. The company operates in two business segments: biodefense and commercial. The company will announce its first quarter results on May 5.
Net loss for the first quarter of 2011 is forecast at $12.8 million on sales of $24.8 million, compared to a net income of $2.5 million on $46.8 million sales recorded during 2010 first quarter, according to analysts polled by Bloomberg. Loss per share is pegged at 52 cents compared to earnings of 8 cents per share reported during the comparable quarter last year.
The company recently signed a modification to its current procurement contract with the U.S. government to supply an additional 3.42 million doses of BioThrax. The modification is valued at $101 million for the delivery and shipping of additional doses of BioThrax beginning third quarter of 2011.All the six analysts covering the stock rate a buy on it. Analysts polled by Bloomberg expect the stock to gain around 34% over the next 12 months with a consensus target price of $31.5. The stock has gained 49% during the last one year and currently trades at a P/E of 15.1